DOI: https://doi.org/10.22141/2308-2097.52.4.2018.154144

Bismuth preparations in gastroenterological practice

Yu.M. Stepanov, N.Yu. Zavhorodnia, O.Yu. Lukianenko

Abstract


The article based on the review of literature data analyzes the mechanisms of the anti-helicobacter and cytoprotective effects of bismuth compounds. The description of the role of bismuth preparations in modern eradication schemes is given, as well as the results of our own studies on the effectiveness and safety of using colloidal bismuth subcitrate as a part of second-line anti-helicobacter therapy in children.

Keywords


anti-helicobacter therapy; bismuth subcitrate colloid; children

References


Keogan DM, Griffith DM. Current and potential applications of bismuth-based drug. Molecules. 2014 Sep 23;19(9):15258-97. doi: 10.3390/molecules190915258.

Sun H, Zhang L, Szeto KY. Bismuth in medicine. Met Ions Biol Syst. 2004;41:333-78.

Klauder JV. Intravenous injections of bismuth compounds in the treatment of syphilis: its use clinically and in experimental syphilis in rabbits. Arch Derm Syphilol. 1928;17(3):332-350. doi: 10.1001/archderm.1928.02380090041006.

Canadian Agency for Drugs and Technologies in Health. Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Nov 24.

Abaturov AE, Gerasimenko ON, Zavgorodniaia NIu. Khronicheskie SagA+NR-assotsiirovannye gastrity u detei [Chronic CagA + HP-associated gastritis in children]. Kharkiv: SAM; 2014. 399 p. (in Russian).

Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol. 2013 Jun;11(6):371-84. doi: 10.1038/nrmicro3028.

Hermann WA, Herdtweck E, Pajdla L. Colloidal Bismuth Subcitrate (CBS): Isolation and structural characterization of the active substance against Helicobacter pylori, a causal factor of gastric diseases. Inorg Chem. 1991;30(12):2579-2581. doi: 10.1021/ic00012a001.

Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2017 Nov/Dec;24(6):e751-e757. doi: 10.1097/MJT.0000000000000389.

Li H, Sun H. Recent advances in bioinorganic chemistry of bismuth. Curr Opin Chem Biol. 2012 Apr;16(1-2):74-83. doi: 10.1016/j.cbpa.2012.01.006.

Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015 Oct;42(7):922-33. doi: 10.1111/apt.13346.

Armstrong JA, Cooper M, Goodwin CS, et al. Influence of soluble haemagglutinins on adherence of Helicobacter pylori to HEp-2 cells. J Med Microbiol. 1991 Mar;34(3):181-7. doi: 10.1099/00222615-34-3-181.

Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012 Mar;4(3):239-43. doi: 10.1039/c2mt00180b.

Yang X, Koohi-Moghadam M, Wang R, et al. Metallochaperone UreG serves as a new target for design of urease inhibitor: A novel strategy for development of antimicrobials. PLoS Biol. 2018 Jan 10;16(1):e2003887. doi: 10.1371/journal.pbio.2003887.

AlMatar M, Makky EA, Var I, Koksal F. The Role of Nanoparticles in the Inhibition of Multidrug-Resistant Bacteria and Biofilms. Curr Drug Deliv. 2018;15(4):470-484. doi: 10.2174/1567201815666171207163504.

Ma L, Wu J, Wang S, Yang H, Liang D, Lu Z. Synergistic antibacterial effect of Bi2S3 nanospheres combined with ineffective antibiotic gentamicin against methicillin-resistant Staphylococcus aureus. J Inorg Biochem. 2017 Mar;168:38-45. doi: 10.1016/j.jinorgbio.2016.12.005.

Wang R, Lai TP, Gao P, et al. Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors. Nat Commun. 2018;9(1):439. doi:10.1038/s41467-018-02828-6.

Işlek I, Uysal S, Gök F, Dündaröz R, Küçüködük S. Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate. Pediatr Nephrol. 2001 Jun;16(6):510-4.

Liu Y, Shen C, Zhang X, et al. Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagy. Toxicol Ind Health. 2018 Mar;34(3):188-199. doi: 10.1177/0748233717746810.

Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168.

Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. doi:10.1136/bmj.h4052.

Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577-85. doi: 10.1080/14787210.2016.1178065.

Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594.

Ministry of Нealth of Ukraine. Order on January 29, 2013 № 59. On Adopting the Standardized Clinical Protocols of Medical Care for Children with Diseases of the Digestive Organs. Available from: http://zakon.rada.gov.ua/rada/show/v0059282-13?lang=en. Accessed: January 29, 2013. (in Ukrainian).




Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта